Frequently asked questions by hospitalists managing pain in adults with sickle cell disease

Journal of Hospital Medicine

Volumn 6, Issue 5, 2011, Pages 297-303

  Smith, Wally R ^a   Jordan, Lanetta B ^b   Hassell, Kathryn L ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sickle Cell Disease Association of America Inc   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Hematology; Multidisciplinary care; Pain; Quality improvement; Sickle cell disease

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OXYCODONE; PETHIDINE; TRAMADOL;

ANALGESIA; COMA; DEATH; DRUG DEPENDENCE; DRUG SAFETY; EVIDENCE BASED PRACTICE; FEAR; HALLUCINATION; HEART ARRHYTHMIA; HOSPITAL CARE; HOSPITAL MANAGEMENT; HOSPITALIZATION; HUMAN; MEDICAL STAFF; MOTIVATION; MYOCLONUS; NAUSEA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; QUESTIONNAIRE; REVIEW; SEIZURE; SICKLE CELL ANEMIA; SIDE EFFECT; TORSADE DES POINTES; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME; VOMITING;

ADULT; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; DISEASE MANAGEMENT; HOSPITALISTS; HOSPITALIZATION; HUMANS; PAIN; PAIN MEASUREMENT; SUBSTANCE-RELATED DISORDERS;

EID: 79958711340     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.933     Document Type: Review

References (64)

1. Serjeant GR. Sickle-cell disease. Lancet. 1997; 350(9079): 725-302.
2. Smith WR, Scherer M. Sickle-cell pain: advances in epidemiology and etiology. Hematology Am Soc Hematol Educ Program. 2010; 409-415. PMID: 21239827.
3. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999; 340: 1021-1030.
4. Hebbel RP, Vercellotti G, Nath KA. A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis. Cardiovasc Hematol Disord Drug Targets. 2009; 9(4): 271-292.
5. Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion [review]. Hemoglobin. 2009; 33(1): 1-16.
6. Davis H, Schoendorf KC, Gergen PJ, Moore RM Jr. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health. 1997; 87(8): 1317-1322.
7. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998; 339: 5-11.
8. Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005; 353(26): 2769-2778.
9. Sandy LG. Homeostasis without reserve-the risk of health system collapse. N Engl J Med. 2002; 347(24): 1971-1975.
10. The Advanced Medical Home: A Patient-Centered, Physician-Guided Model of Health Care [Policy Monograph]. Philadelphia, PA: American College of Physicians; 2006.
11. Wagner EH, Glasgow RE, Davis C, Bonomi AE, Provost L, McCulloch D. Quality improvement in chronic illness care: a collaborative approach. Jt Comm J Qual Improv. 2001; 27: 63-80.
12. Definition of Disease Prevalence for Therapies Qualifying Under the Orphan Drug Act. Subpart C, Designation of an Orphan Drug. Sec. 316.20. Content and format of a request for orphan-drug designation. Available at: Accessed September 3, 2008.
13. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003; 289: 1645-1651.
14. Lanzkron S, Haywood C Jr, Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008; 100(8): 968-973.
15. Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I. Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol. 2011; 86(1): 116-120. PMID: 21061308.
16. Bobo L, Miller ST, Smith WR, Elam JT, Rosmarin PC, Lancaster DJ. Health perceptions and medical care opinions of inner-city adults with sickle cell disease or asthma compared with those of their siblings. South Med J. 1989; 82(1): 9-12.
17. Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage. 1997; 14(3): 168-174.
18. The Management of Sickle Cell Disease. 4th ed. NIH Publication 2002-2117. Washington, DC: National Institutes of Health, National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources; June 2002.
19. Pain Management Guideline. Washington, DC: Agency for Health Care Policy and Research; 1992.
20. Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2005; 58-65.
21. World Health Organization: Cancer Pain Relief. Geneva, Switzerland: WHO, 1986.
22. Dunlop RJ, Bennett KC. Pain management for sickle cell disease. Cochrane Database Syst Rev. April 19, 2006;(2):CD003350.
23. Benjamin L, Dampier C, Jacox A; for the Guideline Committee. Guidelines for the Management of Acute and Chronic Pain in Sickle Cell Disease. APS Clinical Practice Guideline Series, No 1. Glenview, IL: American Pain Society; 1999.
24. Rees D. Guidelines for the management of the acute painful crisis of sickle cell disease. Br J Haematol. 2003; 120: 744-752.
25. Field JJ, Knight-Perry JE, DeBaun MR. Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines. Curr Opin Hematol. 2009; 16(3): 173-178.
26. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008; 16(5): 405-416.
27. Axon RN. A sickle cell primer. The Hospitalist. 2006; 10(10): 39-41.
28. Hill CS Jr. The barriers to adequate pain management with opioid analgesics. Semin Oncol. 1993; 20(2 suppl 1): 1-5.
29. Dampier C, Setty BN, Eggleston B, Brodecki D, O'Neal P, Stuart M. Vaso-occlusion in children with sickle cell disease: clinical characteristics and biologic correlates. J Pediatr Hematol Oncol. 2004; 26: 785-790. PMID: 15591896.
30. Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998; 92: 2551-2555. PMID: 9746797.
31. Michaels LA, Ohene-Frempong K, Zhao H, Douglas SD. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood. 1998; 92: 3148-3151. PMID: 9787150.
32. Landburg PP, Teerlink T, Muskiet FA, Duits AJ, Schnog JJ; for the CURAMA study group. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. Am J Hematol. February 27, 2008; PMID: 18383318.
33. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med. 1991; 325: 11-16.
34. Smith WR, Bovbjerg VE, Penberthy LT, et al. Understanding pain and improving management of sickle cell disease: the PiSCES Study. J Natl Med Assoc. 2005; 97(2): 183-193.
35. Smith WR, McClish DK, Penberthy LT, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008; 148(2): 94-101.
36. Aisiku IP, Smith WR, McClish DK, et al. Comparisons of high versus low emergency department utilizers in sickle cell disease. Ann Emerg Med. 2009; 53(5): 587-593.
37. Helfand M, Freeman M. Assessment and management of acute pain in adult medical inpatients: a systematic review. Pain Med. 2009; 10(7): 1183-1199. PMID: 19818030.
38. Wallenstein SL. Scaling clinical pain and pain relief. In: Bromm B, ed. Pain Measurement in Man: Neorephysiological Correlates of Pain. New York: Elsevier Science Publishers, 1984: 389-396.
39. Dubois M. Patient-controlled analgesia for acute pain. Clin J Pain. 1989; 5(suppl 1): S8-S15. PMID: 2520435.
40. Melzer-Lange MD, Walsh-Kelly CM, Lea G, Hillery CA, Scott JP. Patient-controlled analgesia for sickle pain crisis in pediatric emergency department. Pediatr Emerg Care. 2004; 20: 2-4.
41. Trentadue N, Kachoyeanos MK, Lea G. A comparison of two regimens of patient-controlled analgesia for children with sickle cell disease. J Pediatr Nurs. 1998; 13: 15-19.
42. Narcotic analgesics, 2002 update. The DAWN Report; 2004.
43. Seifert CF, Kennedy S. Meperidine is alive and well in the new millennium: evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy. 2004; 24: 776-783.
44. Porter BP, Coyne PJ, Smith WR. Methadone-related torsades de pointes in a sickle cell patient treated for chronic pain. Am J Hematol. 2005; 78(4): 316-317.
45. de Franceschi L, Finco G, Vassanelli A, Zaia B, Ischia S, Corrocher R. A pilot study on the efficacy of ketorolac plus tramadol infusion combined with erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle cell pain. Haematologica. 2004; 89(11): 1389-1391.
46. Zempsky WT, Loiselle KA, Corsi JM, Hagstrom JN. Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. Clin J Pain. 2010; 26(2): 163-167.
47. Wang WC, George SL, Wilimas JA. Transcutaneous electrical nerve stimulation treatment of sickle cell pain crises. Acta Haematol. 1988; 80(2): 99-102.
48. Midence K, Fuggle P, Davies SC. Psychosocial aspects of sickle cell disease (SCD) in childhood and adolescence: a review. Br J Clin Psychol. 1993; 32 (pt 3): 271-280.
49. Weaver MF, Bond DS, Arnold BL, Waterhouse E, Towne A. Aberrant drug-taking behaviors and headache: patient versus physician report. Am J Health Behav. 2006; 30(5): 475-482.
50. Ballas SK. Current issues in sickle cell pain and its management [review]. Hematology Am Soc Hematol Educ Program. 2007; 97-105.
51. Meehan WJ, Adelman SA, Rehman Z, Khoromi S. Opioid Abuse. Available at: Updated April 18, 2006. Accessed August 23, 2006.
52. Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain. 2002; 18(4 suppl): S28-S38.
53. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13): 1315-1321.
54. Payne R. American Pain Society workshop on the management of sickle cell pain. Saint Louis, MO; 1990.
55. Vichinsky EP, Johnson R, Lubin BH. Multidisciplinary approach to pain management in sickle cell disease. Am J Pediatr Hematol Oncol. 1982; 4: 328-333.
56. Brozovic M, Davies S, Yardumian A, Bellingham A, Marsh G, Stephens AD. Pain relief in sickle cell crisis [letter]. Lancet. 1986; 2: 624-625.
57. Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage. 2004; 27(2): 156-169.
58. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992; 79: 2154-2163.
59. Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol. 2009; 144(5): 782-788.
60. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005; 79: 17-25.
61. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010; 303(13): 1288-1294.
62. Todd KH, Funk KG, Funk JP, et al. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996; 27: 485-489.
63. Lopez B, Flenders P, Davis-Moon L, Corbin T, Ballas S. Clinically significant differences in visual analogue scale in acute vasoocclusive sickle cell crisis. Hemoglobin. 2007; 31: 427-432.
64. Hansson P, Backonja M, Bouhassira D. Usefulness and limitations of quantitative sensory testing: clinical and research application in neuropathic pain states. Pain. 2007; 129: 256-259.